Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 149.83$. Average daily volumn in 3 months 7.32M. Market cap 271.78B



Stock symbol : ABBV. Exchange : NYSE. Currency : USD
Lastest price : 153.80$. Total volume : 3.65M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

AbbVie Inc. (ABBV)
Last Price
153.80$
Change
0.64
Volume
3.65M

Previous Close153.16
Open153.08
Day Range151.46-153.85
Bid151.00 x 1.3k
Ask153.59 x 900
Volume3.65M
Average Volume7.32M
Market Cap271.78B
Beta0.81
52 Week Range105.56-175.91
Trailing P/E22.07
Foward P/E12.86
Dividend (Yield %)3.67%
Ex-Dividend Date2022-07-14



Financial Details


According to AbbVie Inc.'s financial reports the company's revenue in 2021 were 56.2B an increase( +24.44%) over the years 2020 revenue that were of 45.8B. In 2021 the company's total earnings were 11.54B while total earnings in 2020 were 4.62B( +175%).


Loading ...



Organization

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Market Cap:
271.78B
Revenue:
56.2B
Total Assets:
146.53B
Total Cash:
9.75B



News about "AbbVie Inc."

abbvie-inc-nyseabbv-shares-acquired-by-great-valley-advisor-group-inc-image

AbbVie Inc. (NYSE:ABBV) Shares Acquired by Great Valley Advisor Group Inc.

Source from : Defense World - 10 hours ago

Great Valley Advisor Group Inc. increased its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 3.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»


abbvie-inc-nyseabbv-receives-consensus-rating-of-moderate-buy-from-brokerages-image

AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Source from : Defense World - 13 hours ago

AbbVie Inc. (NYSE:ABBV – Get Rating) has received a consensus rating of “Moderate Buy” from the nineteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has ...See details»


AbbVie Inc. (ABBV) Outlook: Revisiting The Past For Future Insights

Source from : stocksregister - 2 days ago

AbbVie Inc. (NYSE:ABBV) at last check was buoying at $152.49 on Thursday, June 30, with a fall of -1.07% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


is-abbvie-about-to-get-a-new-blockbuster-drug-image

Is AbbVie About To Get A New Blockbuster Drug?

Source from : Nasdaq - 5 days ago

L ast month, AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the compound ABBV-951 to treat motor fluctuations in patients with advanced ...See details»


abbvies-abbv-rinvoq-gets-chmp-nod-for-new-indication-image

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

Source from : Nasdaq - 5 days ago

ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor ...See details»


spire-wealth-management-reduces-position-in-abbvie-inc-nyseabbv-image

Spire Wealth Management Reduces Position in AbbVie Inc. (NYSE:ABBV)

Source from : ETF Daily News - 4 days ago

Spire Wealth Management decreased its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 20.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 60,790 ...See details»


ritholtz-wealth-management-grows-stake-in-abbvie-inc-nyseabbv-image

Ritholtz Wealth Management Grows Stake in AbbVie Inc. (NYSE:ABBV)

Source from : ETF Daily News - 5 days ago

Ritholtz Wealth Management increased its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 279.3% in the first quarter, according to the company in its most recent filing with the Securities & ...See details»


is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now-image

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

Source from : Yahoo News Singapore - 3 days ago

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.See details»


AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding

Source from : YAHOO!Finance - 5 days ago

Headquartered in Illinois, AbbVie (NYSE:ABBV) is a well-respected pharmaceutical businesses with a broad range of medical treatments and solutions. If you’re going to pick a pharmaceutical-market ...See details»


AbbVie Declares Quarterly Dividend

Source from : YAHOO!Finance - 9 days ago

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.See details»


abbvie-rallies-after-its-test-of-the-rising-200-day-moving-average-line-image

AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line

Source from : TheStreet.com - 5 days ago

In this daily bar chart of , below, we can see that prices rallied back above the 50-day moving average line after touching/testing the rising 200-day line earlier this month. The ...See details»


Why AbbVie Stock Is Trading Higher Today

Source from : Benzinga.com - 11 days ago

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support ...See details»


Abbvie Inc ABBV Trading Report

Source from : MarketWatch - 19 days ago

This report optimizes trading in Abbvie Inc (NASDAQ: ABBV) with integrated risk controls. Use the basic rules of Technical Analysis. Here are some examples: if ABBV is testing support the signal ...See details»


Baron Funds: “We Retain Conviction in AbbVie (ABBV)”

Source from : Insider Monkey - 18 days ago

In its Q1 2022 investor letter, Baron Health Care Fund mentioned AbbVie Inc. (NYSE:ABBV) and explained its insights for the company. Founded in 2013, AbbVie Inc. (NYSE:ABBV) is a North Chicago ...See details»